Latest Autoantibodies Stories
-- CHABLIS-SC1 study passes futility analysis and will continue to completion with an enhanced endpoint HAYWARD, Calif., Feb.
A new study reveals that one in six patients with systemic lupus erythematosus (SLE) is readmitted to the hospital within 30 days of being discharged.
- Significant clinical response to Acthar was observed in patients experiencing active disease while on conventional SLE maintenance therapies - ANAHEIM, Calif., May 5, 2014 /PRNewswire/ --
According to a new report from BCC Research, the global market for drugs to treat systemic lupus erythematosus (SLE), is expected to grow to $2.6 billion by 2018, with a five-year compound annual
Discounted research study “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022” elaborated by GlobalData is now available at MarketPublishers.com.
Reportbuyer.com just published a new market research report:
This EpiCast report (http://www.reportsnreports.com/reports/267627-epicast-report-systemic-lupus-erythematosus-epidemiology-forecast-to-2022.html
- Growing in low tufty patches.